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Abstract
Gliomas are the most common brain tumors and include a variety of histologic types and grades of malignancy.
They arise from glial cells and represent approximately 70% of the primary brain tumors. According to the criteria of
the World Health Organization (WHO), the majority of gliomas can be classified into four grades of malignancy (I-IV).
Virus infection, especially by DNA viruses and retroviruses, which may cause insertion of viral DNA sequences into
the host genome, often triggers the host defense mechanisms. Particularly, the DNA methylation machinery can be
activated to cause the methylation of foreign movable viral sequences and, therefore, silence viral gene expression.
Several studies have shown the presence of Human Cytomegalovirus (HCMV) in glioblastoma, suggesting that the virus
may participate in tumor pathogenesis. But this relationship is controversial because many other studies did not detect
HCMV in these tumors. This study aims to detect the presence of HCMV in several samples of human glioma
(94 formalin-fixed, paraffin-embedded samples and 28 snap-frozen samples) by different sensitive techniques.
We have been unable to detect HCMV DNA and proteins in glioma samples. Therefore, arguments used so
far to conclude that HCMV is an oncomodulator virus in gliomas must be, in our view, seriously reconsidered.
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Background
Gliomas constitute a heterogeneus group of malignant
neoplasms of the central nervous system which are
derived from glial cells and represent the most frequent
form of primary brain tumors, over 70% of cases [1, 2].
Gliomas are classified into four malignant grades
attending to their morphological and histological
features. Glioblastoma multiforme, the most malignant
type of glioma (WHO grade IV), is highly aggressive
and invasive, with a mean survival rate of 14–15 months
after diagnosis.
In gliomas, the etiological factors still remain elusive.
Yet, although large epidemiological studies have failed to
identify new clear causative factors, in recent years
cytomegalovirus infections have focused the scientific
community attention. However, their etiological role in
the genesis of gliomas is currently controversial.
HCMV is a double-stranded DNA virus of the
Herpesviridae family with a genome of ca. 230 kb and
containing ca. 200 genes coding for viral proteins and
at least 14 microRNAs [3, 4]. HCMV is extremely
prevalent, with infections rates between 50 and 90%
of adult population [5]. Since the finding of HCMV in
brain tumors in 2002 by Cobbs et al. [6], controversy
about the presence of HCMV in glioma genomes has
increased in the literature. Viral DNA, RNA and proteins
were HCMV-positive in the majority of tumor cells in
human glioblastoma, including both anaplastic and low-
grade gliomas [6, 7]. However, these studies have used
distinct and non-uniform methodological approaches, and
the same accounts for the target molecules used for virus
detection. This complete lack of standarization thus
constitutes in our view a crucial problem. Additionally,
the controversy on the implication of HCMV in gliomas
has been fed with data pointing out that anti-viral drugs
could improve the survival outcome to this disease.
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Procedure and results
With the aim of shedding light on such uncertainty, we
set to analyze in this study a large series of primary
gliomas in order to detect the presence of HCMV by a
diagnostic, validated real-time PCR method. With this
purpose, we analyzed a panel of 68 formalin-fixed,
paraffin-embedded samples and 28 snap-frozen samples
from patients with astrocytoma obtained from the
biobank of the Hospital General Universitario de Elche,
together with 26 formalin-fixed, paraffin-embedded
samples from patients with astrocytoma from the
biobank of the Hospital General Universitario de Alicante
(total, 122 samples; Table 1). Additionally, a formalin-
fixed, paraffin-embedded tissue sample of lung infected
with HCMV was used as a positive control.
Genomic DNA was isolated from tumor and control
tissues using the high performance QIAamp DNA
Investigator forensic kit. HCMV DNA detection in
glioma samples was performed with 5 uL of isolated
genomic DNA per RT-PCR reaction in an Applied Biosys-
tems 7500 Real-Time PCR System using a very sensitive
diagnostic validated test, RealStar CMV PCR kit 1.0 (Altona
Diagnostics GmbH, Hamburg, Germany). This assay
includes an internal control (heterologous amplification
system) and in each reaction we included the four stan-
dardized concentrations of HCMV specific DNA (101-104
genome copies) supplied with the kit. As a positive control
we used genomic DNA from formalin-fixed, paraffin-
embedded lung tissue of an infected donor. For HCMV
DNA analysis, a four-point standard curve (Pearson’s
correlation coefficient, >0.99) was used to interpolate the
HCMVviral load from 10 to 10,000 copies (Additional file 1).
Surprisingly, 119 samples of the whole set of gliomas
analyzed showed undetectable levels of HCMV DNA,
and only three cases showed a low number (<10) of
viral copies (Table 2).
A nested PCR approach was used in a selected
subset of samples. Genomic DNAs from two formalin-
fixed, paraffin-embedded and 28 snap-frozen samples
were processed following a nested-PCR scheme [8]
(Additional file 1). Using this technique, no sample was
found positive for HCMV DNA (Table 2). Yet, we believe
that this methodology is not completely reliable, since the
number of PCR amplification cycles is extremely high (up
to 90 cycles), which represents an important risk of DNA
cross-contamination.
Immunohistochemical (IHC) evaluation was performed
on sections of tissue microarrays from 110 samples (25
snap-frozen samples and 85 formalin-fixed, paraffin-
embedded samples). We used an optimized antibody
(Anti-cytomegalovirus antibody cocktail CCH2/DDG9
Dako), corresponding to HCMV-encoded p52/p76 kDa
early DNA-binding protein and early protein [9])
(Additional file 1). No sample was found positive by IHC
using this approach (Table 2).
Discussion
Several groups [7, 8, 10–12] have been able to detect
HCMV DNA and proteins in glioma samples in the
same proportion as that obtained by Cobbs et al. 2002,
i.e. of 90-100%. Other groups have reported virus
detection in glioma samples, but in a lower proportion
(12-70%) [13–16]. Finally, some groups [9, 17–21] have
been unable to detect neither HCMV DNA or proteins.
This discrepancy is likely attributable to methodological
differences among these studies [22]. In this context, a
recent published paper supports our results [23]. They
used 6 highly sensitive assays with three orthogonal
technologies (real-time PCR, IHC and CISH) on
multiple specimens and specimen types. No evidence for
CMV in glioblastoma tissues was found.
The HCMV infection level in glioma samples in most
studies is usually very low, and thus more sensitive
methods may be required to detect persistent HCMV
infection in tumor cells [24]. Also, optimized antigen
retrieval and a high antibody concentration are thought
to be the key factors required for HCMV detection by
IHC methods [9].
Since at present HCMV is not considered to be an
oncogenic virus, the term oncomodulation has been
proposed to designate the ability of HCMV to modify
tumor cell biology [25–28]. There are currently several
hypotheses on how HCMV enters the human brain, but
none of them implies that the virus plays a role in
gliomagenesis. Thus, it is not clearly defined still whether
HCMV infection is an epiphenomenon or is actually
Table 1 Patient characteristics
Variable Number Percent
Gender
Male 72 59
Female 50 41
Age (years)
Mean 54
Range 4-81
Tumor grade
II 16 13.1
III 19 15.6
IV 87 71.3
Table 2 Results of the different techniques used
Technique Number of samples HCMV-positive HCMV-negative
RT-qPCR 122 3 119
Nested PCR 30 0 30
IHC 110 0 110
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causative of this type of tumors [26]. Given that the infec-
tion rate is very low and no studies have yet attempted
HCMV detection by means of transcriptomic or genomic
DNA analyses using next-generation sequencing, it must
be evaluated whether HCMV can by itself elicit oncogenic
and immunosuppressive processes, and consequently
whether this virus is actually a relevant therapeutic target
in glioblastomas [22]. Also, despite there are numerous
ongoing clinical trials, no evidence has been yet obtained
on the biological efficacy of anti-viral agents on gliomas. It
must also be taken into account that anti-viral treatments
may also act in other ways independent of HCMV target-
ing, for instance by synergizing with chemotherapy and/or
radiation therapies [29, 30].
Conclusions
In conclusion, there is currently a great controversy on
the relationship between HCMV and gliomagenesis. A
multicenter study is necessary in which a standardized
methodology is used to unequivocally determine whether
this virus is actually present in glioma samples. We believe
that at present anti-viral treatments should not be used
outside clinical trials in glioma patients. Our group has
analyzed in this work a large number of samples using
high specificity and sensitive methods, and as a result we
have been unable to detect HCMV DNA and proteins in
glioma samples. Therefore, arguments used so far to con-
clude that HCMV is an oncomodulator virus in gliomas
must be in our view seriously reconsidered.
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